Nerviano Medical and Italfarmaco Sign Licensing Agreement for the Development and Commercialization of Peptide-Drug Conjugate (PDC)
Shots:
- A licensing agreement has been signed b/w Nerviano Medical and Italfarmaco to develop and commercialize novel PDC, resulting in the production of safe, stable, and effective drug conjugates to treat solid tumors that are heterogeneous and CT-resistant
- As pe the terms of the agreement, Nerviano Medical’s linker-payload technology will be utilized by Italfarmaco for the development of novel PDC
- ITF will produce the target peptide while overseeing all non-clinical, clinical, and commercialization activities related to the product candidates. Financial details remain undisclosed
Ref: Italfarmaco | Image: Italfarmaco
Related News:- Italfarmaco Group Receives EMA’s Validation of MAA for Givinostat to Treat Duchenne Muscular Dystrophy
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
